Form 13-F position report

ALIMERA SCIENCES INC COM NEW S

Reported by VANGUARD GROUP INC

ALIM CUSIP 016259202 Manager CIK 0000102909

Reported 1,045,460 shares, up 396,506 (61.1%) from the prior quarter.

Reported value 45.4%; share count 61.1% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q1 2024
Shares 1,045,460 Quarter-end amount reported
Reported value $4,077,294 Fair value at quarter end
Consecutive quarters held 44 Through Q1 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-03-31 1212000
2021-06-30 1336000
2021-09-30 619000
2021-12-31 753000
2022-03-31 815000
2022-06-30 817000
2022-09-30 755000
2022-12-31 402771
2023-03-31 312110
2023-06-30 412868
2023-09-30 454727
2023-12-31 2803482
2024-03-31 4077294
2024-06-30 6548262
2024-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

15 quarters
Quarterly reported position history for ALIMERA SCIENCES INC COM NEW S held by VANGUARD GROUP INC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2024 Reduced 0 -1,177,745 (-100.0%) 0 $0 2024-11-13
Q2 2024 Added 1,177,745 +132,285 (12.7%) < 0.01% $6,548,262 2024-08-13
Q1 2024 Added 1,045,460 +396,506 (61.1%) < 0.01% $4,077,294 2024-05-10
Q4 2023 Added 648,954 +502,268 (342.4%) < 0.01% $2,803,482 2024-02-14
Q3 2023 Added 146,686 +5,293 (3.7%) < 0.01% $454,727 2023-11-14
Q2 2023 Reduced 141,393 -7,231 (-4.9%) < 0.01% $412,868 2023-08-14
Q1 2023 Unchanged 148,624 0 (0.0%) < 0.01% $312,110 2023-05-15
Q4 2022 Added 148,624 +58 (0.0%) < 0.01% $402,771 2023-02-10
Q3 2022 Reduced 148,566 -793 (-0.5%) < 0.01% $755,000 2022-11-14
Q2 2022 Added 149,359 +3,726 (2.6%) < 0.01% $817,000 2022-08-12
Q1 2022 Reduced 145,633 -1,230 (-0.8%) < 0.01% $815,000 2022-05-13
Q4 2021 Unchanged 146,863 0 (0.0%) < 0.01% $753,000 2022-02-14
Q3 2021 Unchanged 146,863 0 (0.0%) < 0.01% $619,000 2021-11-12
Q2 2021 Added 146,863 +20,905 (16.6%) < 0.01% $1,336,000 2021-08-13
Q1 2021 Added 125,958 +7,519 (6.3%) < 0.01% $1,212,000 2021-05-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

46 managers reported ALIMERA SCIENCES INC COM NEW S for Q1 2024.

Managers reporting ALIMERA SCIENCES INC COM NEW S in Q1 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Caligan Partners LP Unchanged 16,835,154 0 17.36% $65,657,101 6 qtrs
Velan Capital Investment Management LP Unchanged 13,608,533 0 24.1% $53,073,279 8 qtrs
Stonepine Capital Management LLC Added 4,051,072 +51,613 12.53% $15,799,181 3 qtrs
BOOTHBAY FUND MANAGEMENT LLC Unchanged 3,198,708 0 0.24% $12,474,961 3 qtrs
Altium Capital Management LP Reduced 2,550,000 -110,000 3.94% $9,945,000 3 qtrs
Clearline Capital LP Reduced 2,085,291 -83,852 0.4% $8,132,635 3 qtrs
AIGH Capital Management LLC Reduced 1,520,359 -705,709 1.78% $5,929,400 3 qtrs
VANGUARD GROUP INC This report Added 1,045,460 +396,506 < 0.01% $4,077,294 18 qtrs
MORGAN STANLEY Reduced 501,738 -414,508 < 0.01% $1,956,779 18 qtrs
BlackRock Inc Added 483,294 +39,455 < 0.01% $1,884,847 18 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2024
Filed
May 10, 2024
Filing type
13F-HR
Position type
COM NEW

Voting authority reported

Sole
0
Shared
0
None
1,045,460

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.